IL311078A - Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva) - Google Patents
Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva)Info
- Publication number
- IL311078A IL311078A IL311078A IL31107824A IL311078A IL 311078 A IL311078 A IL 311078A IL 311078 A IL311078 A IL 311078A IL 31107824 A IL31107824 A IL 31107824A IL 311078 A IL311078 A IL 311078A
- Authority
- IL
- Israel
- Prior art keywords
- mva
- downregulation
- rna
- utilization
- micro
- Prior art date
Links
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 title 1
- 108700019146 Transgenes Proteins 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 230000003828 downregulation Effects 0.000 title 1
- 108091070501 miRNA Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21194940 | 2021-09-03 | ||
| PCT/EP2022/074510 WO2023031428A1 (en) | 2021-09-03 | 2022-09-02 | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL311078A true IL311078A (en) | 2024-04-01 |
Family
ID=77640525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL311078A IL311078A (en) | 2021-09-03 | 2022-09-02 | Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240392257A1 (https=) |
| EP (1) | EP4396333A1 (https=) |
| JP (1) | JP2024535145A (https=) |
| KR (1) | KR20240051214A (https=) |
| CN (1) | CN118234850A (https=) |
| AU (1) | AU2022338199A1 (https=) |
| CA (1) | CA3230406A1 (https=) |
| IL (1) | IL311078A (https=) |
| MX (1) | MX2024002641A (https=) |
| WO (1) | WO2023031428A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024188801A1 (en) * | 2023-03-10 | 2024-09-19 | Bavarian Nordic A/S | Use of quail cell lines for poxvirus production |
| WO2024245722A2 (en) * | 2023-05-26 | 2024-12-05 | Probiogen Ag | Rapid selection system for the generation of recombinant enveloped viruses |
| WO2025120141A1 (en) * | 2023-12-08 | 2025-06-12 | Bavarian Nordic A/S | Downregulation of yield-reducing transgenes expressed by poxvirus |
| WO2025153852A1 (en) * | 2024-01-17 | 2025-07-24 | 1. Revvity Gene Delivery Gmbh | Production of viral vectors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| EP2345665A3 (en) | 2001-12-04 | 2012-02-15 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
| US20060185027A1 (en) * | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| GB2469043B (en) * | 2009-03-30 | 2011-02-23 | Lotus Car | A reheated gas turbine system having a fuel cell |
| WO2013059498A1 (en) * | 2011-10-18 | 2013-04-25 | Geovax, Inc. | Mva vectors expressing polypeptides and having high level production in certain cell lines |
| KR102435054B1 (ko) * | 2012-08-01 | 2022-08-22 | 버베리안 노딕 에이/에스 | 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신 |
| EP2912183B1 (en) | 2012-10-28 | 2020-05-06 | Bavarian Nordic A/S | Pr13.5 promoter for robust t-cell and antibody responses |
-
2022
- 2022-09-02 JP JP2024513977A patent/JP2024535145A/ja active Pending
- 2022-09-02 WO PCT/EP2022/074510 patent/WO2023031428A1/en not_active Ceased
- 2022-09-02 EP EP22772951.4A patent/EP4396333A1/en active Pending
- 2022-09-02 MX MX2024002641A patent/MX2024002641A/es unknown
- 2022-09-02 CA CA3230406A patent/CA3230406A1/en active Pending
- 2022-09-02 CN CN202280073591.8A patent/CN118234850A/zh active Pending
- 2022-09-02 IL IL311078A patent/IL311078A/en unknown
- 2022-09-02 US US18/688,756 patent/US20240392257A1/en active Pending
- 2022-09-02 AU AU2022338199A patent/AU2022338199A1/en active Pending
- 2022-09-02 KR KR1020247010053A patent/KR20240051214A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240392257A1 (en) | 2024-11-28 |
| AU2022338199A1 (en) | 2024-03-14 |
| MX2024002641A (es) | 2024-05-10 |
| CA3230406A1 (en) | 2023-03-09 |
| EP4396333A1 (en) | 2024-07-10 |
| KR20240051214A (ko) | 2024-04-19 |
| CN118234850A (zh) | 2024-06-21 |
| WO2023031428A1 (en) | 2023-03-09 |
| JP2024535145A (ja) | 2024-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL311078A (en) | Use of microRNA to downregulate expression of cytotoxic transgenes by modified vicinia ankara virus (mva) | |
| PH12016501623A1 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
| CL2018000587A1 (es) | Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017) | |
| MX384422B (es) | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras | |
| AR079882A1 (es) | Plantas tolerantes a herbicidas inhibidores de las hppd | |
| UY34217A (es) | ?método de control de insectos y malezas, secuencia de adn, planta y semilla de soja y composición derivada de éstas | |
| AR079881A1 (es) | Plantas tolerantes a herbicidas inhibidores de las hppd | |
| CL2019000704A1 (es) | Vectores de adenovirus canino. | |
| NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
| CO2019013786A2 (es) | Métodos y composiciones para reducir la inmunogenicidad de los receptores notch quiméricos | |
| EA201600344A1 (ru) | Гербицидные соединения | |
| MX2016007980A (es) | Acido nucleico que induce acido ribonucleico de interferencia modificado para prevenir una falla en alcanzar el objetivo, y uso del mismo. | |
| MX2011012312A (es) | Vacuna universal para influenza basada en virus vaccinia ankara (mva) modificado recombinante. | |
| Orubu et al. | Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA | |
| CO6511253A2 (es) | Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma | |
| CL2020002352A1 (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| NZ719934A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors | |
| WO2014028295A3 (en) | Use of a maize untranslated region for transgene expression in plants | |
| EA201170854A1 (ru) | Система единичной рекомбинации и способы применения | |
| MX358883B (es) | Aumentar el rendimiento de particulas similares a virus en plantas. | |
| HK40107307A (en) | Utilization of micro-rna for downregulation of cytotoxic transgene expression by modified vaccinia virus ankara (mva) | |
| WO2012085936A8 (en) | Recombinant respiratory syncytial virus plasmids and vaccines | |
| EA201990719A1 (ru) | Новые промоторы | |
| MX2017016625A (es) | Induccion de la expresion genica usando una mezcla de azucar de alta concentracion. | |
| WO2014015287A3 (en) | Influenza vaccine consisting of a mva which expresses influenza antigens fused to vaccinia secretory signal sequences |